Difference in Restricted Mean Survival Times as a Measure of Effect Size: No Assumption Does Not Mean No Rule

Affiliation

• ¹ Paul de Boissieu, MD, PhD, Drug Assessment Division, Haute Autorité de Santé, Saint-Denis, France; and Sylvie Chevret, MD, PhD, Membre titulaire de la Commission de la Transparence, Haute Autorité de Santé, Saint-Denis, France, ECSTRRA team, UMR1153, Inserm, Paris Cité Université, Paris, France.